Anacor

Anacor, also known as Anacor Pharmaceuticals, was a biopharmaceutical company focused on the development of novel treatments for inflammatory and infectious diseases. The company was founded in 1995 and was headquartered in Palo Alto, California. Anacor's research and development efforts were primarily concentrated on topical medications.

The company's most notable product was Kerydin (tavaborole), a topical antifungal medication approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of onychomycosis, a fungal infection of the toenails. Kerydin works by inhibiting protein synthesis in fungi. Anacor also had other product candidates in its pipeline, including treatments for acne and other dermatological conditions.

Anacor's business model involved both internal research and development and strategic partnerships. The company aimed to leverage its scientific expertise and proprietary technology platforms to bring innovative therapies to market. In 2016, Anacor was acquired by Pfizer Inc. for approximately $5.2 billion. The acquisition aimed to strengthen Pfizer's dermatology portfolio and expand its offerings in the topical treatment space. Following the acquisition, Anacor ceased to operate as an independent entity.